Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 444 Shenzhen 24 Beijing 23 Nanning 18 Zhongshan 17
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University444 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University184 Nanfang Hospital, Southern Medical University138 AstraZeneca136 Guangdong Provincial People's Hospital82 Clear sponsor filter
Site location
Guangzhou444 Shenzhen24 Beijing23 Nanning18 Zhongshan17
All 55 locations
Target enrolment
to

Trials with a site in Guangzhou

444 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
TEER In dynaMic sEvere Functional Mitral Regurgitation (TIMER)
NCT07197021Mitral Regurgitation Functional
DrugGDMT
Sun Yat-sen University
Not applicable
540
Guangzhou
2027-01-01
Not yet open
Sun Yat-sen University
Phase 2
22
Guangzhou, Shenzhen
2027-01
Not yet open
Sun Yat-sen University
Phase 2
91
Guangzhou
2026-11-30
Not yet open
Sun Yat-sen University
Phase 2
29
Guangzhou
2026-11-04
Not yet open
Sun Yat-sen University
Phase 2
30
Guangzhou
2026-11-01
Not yet open
Sun Yat-sen University
Phase 2
229
Guangzhou, Shanghai
2026-11-01
Not yet open
Sun Yat-sen University
Phase 2
100
Guangzhou
2026-10-31
Not yet open
Remimazolam vs Propofol for Long-Term Sedation in Mechanically Ventilated ICU Patients
NCT07880548Long-term Sedation for Mechanical Ventilation, Critically Ill Intensive Care Unit Patients
Sun Yat-sen University
Phase 3
274
Dongguan, Guangzhou, Shenzhen, Nanning, Luoyang, Zhengzhou, Wuhan, Nantong
2026-10-20
Recruiting
Sun Yat-sen University
Phase 2
112
Guangzhou
2026-10-12
Not yet open
Sun Yat-sen University
Phase 2
256
Guangzhou
2026-10-12
Recruiting
Sun Yat-sen University
Phase 2
28
Guangzhou
2026-10-01
Not yet open
Sun Yat-sen University
Phase 2
138
Guangzhou
2026-10
Not yet open
Sun Yat-sen University
Phase 2
176
Guangzhou
2026-09-30
Recruiting
Sun Yat-sen University
Phase 3
204
Guangzhou, Changsha, Fuzhou
2026-09-29
Not yet open
Sun Yat-sen University
Not applicable
801
Guangzhou
2026-09-10
Not yet open
Sun Yat-sen University
Phase 2
52
Guangzhou
2026-09-01
Not yet open
Sun Yat-sen University
Phase 2
18
Guangzhou
2026-09-01
Not yet open
Sun Yat-sen University
Phase 2
28
Guangzhou
2026-09-01
Not yet open
Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma
NCT07766889Oral Squamous Cell Carcinoma, Head and Neck Cancer, Locally Advanced Head and Neck Cancer, Neoadjuvant Therapy
DrugsPucotenlimab·Becotatug Vedotin
Sun Yat-sen University
Phase 2
32
Guangzhou
2026-09-01
Not yet open
Sun Yat-sen University
Phase 2
75
Guangzhou
2026-08-31
Not yet open
Sun Yat-sen University
Phase 2
40
Guangzhou, Shijiazhuang, Anyang, Zhengzhou, Nanjing, Nanchang, Dalian, Chengdu
2026-08-28
Not yet open
VIPeerAgent for Adolescent Mental Health
NCT07778758Youth Mental Health, Psychological Distress in Adolescents and Young Adults, Early Intervention
Sun Yat-sen University
Not applicable
234
Guangzhou
2026-08-20
Not yet open
Sun Yat-sen University
Phase 2
47
Guangzhou
2026-08-15
Not yet open
Sun Yat-sen University
Phase 2
29
Guangzhou
2026-08-15
Recruiting
Sun Yat-sen University
Phase 2
45
Guangzhou
2026-08-10
Not yet open
Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC
NCT07674524Non-Small Cell Lung Cancer (NSCLC), Hyperlipidemia, ALK Gene Mutation, ALK-positive
Sun Yat-sen University
Observational
160
Guangzhou
2026-08-01
Recruiting
Culmerciclib in HR+/HER2+ Advanced Breast Cancer
NCT07732491Breast Cancer, Metastastic Breast Cancer, HER2+ Advanced Breast Cancer
DrugCulmerciclib
Sun Yat-sen University
Phase 2
35
Guangzhou
2026-08-01
Recruiting
Sun Yat-sen University
Phase 2
51
Guangzhou
2026-08-01
Not yet open
Sun Yat-sen University
Phase 2
48
Xiamen, Guangzhou, Guilin
2026-08-01
Not yet open
Sun Yat-sen University
Phase 2
60
Guangzhou
2026-08
Not yet open
FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC
NCT07729605Colorectal Cancer Metastatic, Microsatellite Stable (MSS) Colorectal Cancer (CRC)
DrugsFolfox·Lenvatinib·Bevacizumab
Sun Yat-sen University
Phase 3
270
Guangzhou
2026-07-30
Recruiting
Sun Yat-sen University
Phase 3
568
Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan, Changsha
2026-07-24
Recruiting
Sun Yat-sen University
Phase 2
62
Fuzhou, Guangzhou, Nanning, Wuhan
2026-07-22
Recruiting
Sun Yat-sen University
Phase 3
566
Guangzhou
2026-07-20
Recruiting
Sun Yat-sen University
Phase 3
86
Guangzhou
2026-07-20
Recruiting
HR20013 for the Prevention of Nausea and Vomiting in Patients With Cancer: A Real-World Study
NCT07874308Chemotherapy-Induced Nausea and Vomiting (CINV), Nausea, Vomiting, Neoplasms
Sun Yat-sen University
Observational
3,000
Guangzhou
2026-07-15
Recruiting
Sun Yat-sen University
Phase 2
103
Guangzhou
2026-07-01
Not yet open
Sun Yat-sen University
Phase 2
30
Guangzhou
2026-07-01
Not yet open
Sun Yat-sen University
Phase 3
296
Guangzhou
2026-07-01
Not yet open
Sun Yat-sen University
Phase 2
144
Guangzhou
2026-07
Recruiting
Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD
NCT07775950Colorectal Cancer (MSI-H), Molecular Residual Disease
Sun Yat-sen University
Not applicable
100
Guangzhou
2026-06-23
Recruiting
Sun Yat-sen University
Phase 2
42
Guangzhou
2026-06-17
Recruiting
Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
NCT07543536Advanced/Metastatic Breast Cancer, HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
DrugsMegestrol Acetate·Trastuzumab deruxtecan
Sun Yat-sen University
Phase 3
132
Guangzhou
2026-06-08
Not yet open
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
NCT07542912Complete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event
Sun Yat-sen University
Not applicable
30
Guangzhou
2026-06-01
Not yet open
Sun Yat-sen University
Observational
50
Guangzhou
2026-06-01
Recruiting
Sun Yat-sen University
Phase 2
160
Guangzhou
2026-06-01
Not yet open
Sun Yat-sen University
Phase 2
20
Guangzhou
2026-06
Recruiting
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
NCT07584499Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
DrugBecotatug Vedotin
Sun Yat-sen University
Phase 1
51
Guangzhou
2026-05-30
Not yet open
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
NCT07601607Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
DrugsLisaftoclax·Chidamide·Rituximab
Sun Yat-sen University
Phase 1/2
51
Guangzhou
2026-05-30
Not yet open
Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
NCT07615283Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCL
Sun Yat-sen University
Phase 1/2
40
Guangzhou
2026-05-29
Recruiting
Sun Yat-sen University
Phase 2
84
Guangzhou
2026-05-26
Recruiting
Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal Carcinoma
NCT07567742Oral Mucositis (Ulcerative) Due to Radiation, Nasopharyngeal Carcinoma (NPC)
DrugTaurine
Sun Yat-sen University
Phase 2
130
Guangzhou
2026-05-08
Not yet open
Sun Yat-sen University
Phase 3
442
Guangzhou
2026-05-08
Not yet open
AI-Assisted Optimization of Online Adaptive Radiotherapy for Gastric Lymphoma
NCT07609355Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Sun Yat-sen University
Not applicable
25
Guangzhou
2026-05-08
Not yet open
Sun Yat-sen University
Phase 2
47
Guangzhou
2026-05-06
Not yet open
The Experience of Short Video Addiction Among College Students
NCT07574021Behavior, Addictive, College Student
Sun Yat-sen University
Observational
30
Guangzhou
2026-05-01
Not yet open
Phosphate-Containing Replacement Fluid for Patients Undergoing CRRT
NCT07550894Acute Kidney Injury, Sepsis, Critically Ill Patients Requiring Continuous Renal Replacement Therapy
Sun Yat-sen University
Phase 3
220
Chongqing, Guangzhou, Nanning, Luoyang, Zhengzhou, Wuhan, Nanjing, Xi'an
2026-05-01
Not yet open
Sun Yat-sen University
Phase 2
42
Foshan, Guangzhou, Qingyuan, Shantou, Shenzhen, Zhanjiang, Ganzhou
2026-05
Not yet open
Goniotomy in Primary Congenital Glaucoma
NCT07550868Primary Congenital Glaucoma, Goniotomy
Sun Yat-sen University
Observational
120
Guangzhou
2026-05
By invitation
Sun Yat-sen University
Phase 2
42
Foshan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2026-04-20
Recruiting
Sun Yat-sen University
Phase 3
556
Guangzhou
2026-04-20
Recruiting
Sun Yat-sen University
Phase 3
260
Guangzhou, Changsha, Fuzhou, Hangzhou, Nanning
2026-04-16
Recruiting
Sun Yat-sen University
Phase 2
47
Guangzhou
2026-04-10
Recruiting
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
NCT06768931Breast Cancer, Triple Negative Breast Cancer (TNBC), Early Stage Breast Cancer, Immunotherapy
Sun Yat-sen University
Phase 2
192
Lanzhou, Dongguan, Guangzhou, Zhanjiang, Zigong
2026-04-01
Not yet open
Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy
NCT07497958Renal Cell Carcinoma (RCC), Renal Function Abnormal
Sun Yat-sen University
Not applicable
174
Guangzhou
2026-04-01
Recruiting
Sun Yat-sen University
Phase 2
52
Guangzhou
2026-04-01
Recruiting
Sun Yat-sen University
Phase 2
37
Guangzhou
2026-04-01
Recruiting
Effects of Different Tunnel Methods in PICC Catheterization
NCT07594704PICC Line Placement, PICC-associated Thrombosis
Sun Yat-sen University
Not applicable
284
Guangzhou
2026-04-01
Not yet open
Sun Yat-sen University
Phase 2
76
Guangzhou
2026-04
Not yet open
Sun Yat-sen University
Phase 2
30
Guangzhou
2026-03-31
Recruiting
Sun Yat-sen University
Phase 2
34
Guangzhou
2026-03-27
Recruiting
Sun Yat-sen University
Phase 2
40
Guangzhou
2026-03-23
Recruiting
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
NCT07477626Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation Therapy
Sun Yat-sen University
Phase 3
372
Dongguan, Guangzhou, Zhanjiang, Zhengzhou, Chengdu, Hangzhou, Beijing, Shanghai
2026-03-20
Recruiting
Sun Yat-sen University
Phase 2
105
Guangzhou
2026-03-20
Recruiting
Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
NCT07481786Lung Adenocarcinoma, Brain Metastases, Radiotherapy, Intensity-Modulated, Bevacizumab
DrugBevacizumab
Sun Yat-sen University
Phase 3
220
Chongqing, Guangzhou
2026-03-20
Recruiting
SBRT Versus Surgical Resection for Small HCC
NCT07381660Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Phase 3
390
Guangzhou
2026-03-18
Recruiting
Sun Yat-sen University
Phase 2
50
Guangzhou
2026-03-15
Recruiting
Sun Yat-sen University
Phase 2
243
Dongguan, Guangzhou, Shenzhen, Zhanjiang
2026-03-12
Not yet open
Sun Yat-sen University
Not applicable
200
Guangzhou
2026-03-10
Recruiting
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
NCT07494565Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive
DrugsR-Chop·Celecoxib
Sun Yat-sen University
Phase 2
60
Guangzhou
2026-03-06
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou
2026-03-05
Not yet open
ArcFlex Sheath in TAVR Trial
NCT07320274Valve Disease, Aortic
Sun Yat-sen University
Not applicable
180
Guangzhou
2026-03-01
Recruiting
Theory-Based Parenting Intervention for Preschool Children's Health Behaviors
NCT07458009Preschool Children's Health Behaviors, Parental Support
Sun Yat-sen University
Not applicable
80
Guangzhou
2026-02-28
Not yet open
Sun Yat-sen University
Phase 1/2
122
Guangzhou
2026-02-28
Not yet open
Sun Yat-sen University
Phase 3
184
Guangzhou
2026-02-24
Recruiting
Sun Yat-sen University
Phase 2
59
Guangzhou
2026-02-10
Recruiting
Sun Yat-sen University
Phase 2
142
Guangzhou
2026-02-10
Recruiting
Sun Yat-sen University
Phase 2
94
Guangzhou
2026-02-03
By invitation
Sun Yat-sen University
Observational
138
Guangzhou
2026-02-01
Not yet open
Sun Yat-sen University
Early Phase 1
25
Guangzhou
2026-02-01
Not yet open
Sun Yat-sen University
Phase 2
36
Guangzhou
2026-02-01
Not yet open
Sun Yat-sen University
Phase 2
37
Guangzhou
2026-02
Active, closed
Sun Yat-sen University
Phase 2
90
Guangzhou
2026-01-23
Recruiting
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
NCT07324824Hepatocellular Carcinoma, Neoadjuvant Therapy, Sintilimab, Bevacizimab
DrugsBevacizumab biosimilar·Sintilimab
Sun Yat-sen University
Phase 2
37
Guangzhou
2026-01-14
Recruiting
LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC
NCT07325539Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
DrugsToripalimab·Gemcitabine·Cisplatin
Sun Yat-sen University
Phase 2
55
Guangzhou, Shenzhen
2026-01-12
Not yet open
Sun Yat-sen University
Phase 2
50
Guangzhou
2026-01-05
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou
2026-01-05
Recruiting
Magnetic Tracking and ECG-Guided Tip Confirmation System for PICCs
NCT07369427Peripherally Inserted Central Catheters
Sun Yat-sen University
Observational
176
Guangzhou
2026-01-01
Not yet open
Sun Yat-sen University
Phase 2
30
Guangzhou
2026-01-01
Recruiting
Sun Yat-sen University
Phase 2
56
Guangzhou
2026-01-01
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou, Zhengzhou
2025-12-30
Not yet open
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
NCT07277842Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer)
DrugSerplulimab
Sun Yat-sen University
Phase 3
382
Guangzhou
2025-12-29
Not yet open
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
NCT07294261Local Advanced or Metastatic NSCLC
Sun Yat-sen University
Phase 2
69
Guangzhou
2025-12-23
Not yet open
Sun Yat-sen University
Phase 2
37
Guangzhou
2025-12-20
Not yet open
Sun Yat-sen University
Observational
120
Guangzhou
2025-12-18
Recruiting
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
NCT07311772Nasopharyngeal Cancinoma (NPC), Radiation-induced Oral Mucositis
Sun Yat-sen University
Phase 3
386
Beijing, Fuzhou, Guangzhou, Shantou, Zhuhai, Nanning, Wuzhou, Changsha
2025-12-16
Not yet open
Sun Yat-sen University
Phase 2
236
Guangzhou
2025-12-01
Recruiting
Sun Yat-sen University
Phase 1
12
Guangzhou
2025-11-25
Not yet open
Sun Yat-sen University
Observational
229
Guangzhou
2025-11-24
Recruiting
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
NCT07389629Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
DrugLenvatinib
Sun Yat-sen University
Phase 2
25
Guangzhou
2025-11-21
Recruiting
Sun Yat-sen University
Phase 2
96
Guangzhou, Wuhan, Nanchang, Kunming
2025-11-20
Active, closed
Sun Yat-sen University
Phase 3
700
Dongguan, Guangzhou, Shantou, Shenzhen, Zhanjiang
2025-11-17
Recruiting
Sun Yat-sen University
Phase 3
802
Guangzhou
2025-11-13
Recruiting
Sun Yat-sen University
Phase 2
35
Guangzhou
2025-11-13
Recruiting
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-11-05
By invitation
Sun Yat-sen University
Phase 2
60
Guangzhou
2025-11-01
Active, closed
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-10-30
Recruiting
Risk Factors Affecting MSC Efficacy in ACLF Patients
NCT07198854Acute-On-Chronic Liver Failure
Sun Yat-sen University
Observational
446
Guangzhou
2025-10-20
Not yet open
Sun Yat-sen University
Phase 2
128
Guangzhou
2025-10-15
Not yet open
Sun Yat-sen University
Phase 2
56
Guangzhou
2025-10-01
Not yet open
Sun Yat-sen University
Phase 2
150
Guangzhou
2025-10-01
Not yet open
The IVO-LUNG Study
NCT07204548Non Small Cell Lung Cancer (Stage III)
DrugIvonescimab
Sun Yat-sen University
Phase 2
63
Guangzhou
2025-10
Recruiting
Sun Yat-sen University
Phase 2
45
Guangzhou
2025-09-28
Not yet open
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base
NCT07145931Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy, Objective Response Rate
DrugCisplatin
Sun Yat-sen University
Phase 2
24
Guangzhou
2025-09-20
Recruiting
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-09-17
Not yet open
Sun Yat-sen University
Not applicable
58
Guangzhou
2025-09-15
Recruiting
Sun Yat-sen University
Phase 3
192
Guangzhou
2025-09-15
Recruiting
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
NCT07077512Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL)
DrugSintilimab
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-09-15
Recruiting
Sun Yat-sen University
Phase 2/3
80
Guangzhou
2025-09-11
Recruiting
Sun Yat-sen University
Phase 3
242
Guangzhou
2025-09-10
Recruiting
Sun Yat-sen University
Phase 1/2
101
Guangzhou
2025-08-27
Not yet open
Sun Yat-sen University
Phase 2
10
Guangzhou
2025-08-19
Not yet open
Sun Yat-sen University
Phase 2
59
Guangzhou
2025-08-15
Recruiting
Sun Yat-sen University
Phase 3
386
Guangzhou, Guilin, Sanya, Changsha, Nanjing
2025-08-15
Recruiting
Sun Yat-sen University
Observational
4,000
Guangzhou
2025-08-01
Recruiting
Sun Yat-sen University
Not applicable
27
Guangzhou
2025-08-01
Active, closed
Sun Yat-sen University
Phase 2
40
Guangzhou
2025-08-01
Not yet open
Sun Yat-sen University
Not applicable
480
Guangzhou
2025-08-01
Active, closed
Sun Yat-sen University
Phase 2
62
Guangzhou
2025-08-01
Not yet open
Sun Yat-sen University
Phase 2
66
Guangzhou, Xi'an
2025-08
Recruiting
Sun Yat-sen University
Phase 2
69
Guangzhou
2025-07-20
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou
2025-07-20
Not yet open
Sun Yat-sen University
Phase 2
34
Guangzhou
2025-07-11
Recruiting
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
NCT07386158Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy
Sun Yat-sen University
Phase 2
21
Guangzhou
2025-07-10
Active, closed
Sun Yat-sen University
Observational
437
Guangzhou
2025-07-09
Recruiting
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
NCT06802835Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma
DrugGemcitabine/Cisplatin
Sun Yat-sen University
Phase 1/2
148
Guangzhou
2025-07-09
Recruiting
The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
NCT07064681Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Sun Yat-sen University
Observational
100
Guangzhou
2025-07-05
Recruiting
Sun Yat-sen University
Phase 3
311
Chongqing, Lanzhou, Guangzhou
2025-07-01
Not yet open
Sun Yat-sen University
Not applicable
314
Guangzhou
2025-07
Recruiting
Transanal Total Mesorectal Excision vs Robotic Total Mesorectal Excision
NCT07651553Rectal Cancer Patients, Robotic Assisted Intervention
Sun Yat-sen University
Not applicable
216
Guangzhou
2025-06-30
Active, closed
Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma
NCT06673693Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC
DrugTislelizumab
Sun Yat-sen University
Phase 2
24
Guangzhou
2025-06-25
Recruiting
A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
NCT06947811EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor
DrugsAlmonertinib·Palbociclib
Sun Yat-sen University
Phase 1/2
71
Guangzhou
2025-06-09
Recruiting
Omitting CTV for Primary Tumor in LS-SCLC
NCT07008716SCLC, Limited Stage, Radiation Exposure, Radiotherapy Side Effect, Progression
DrugsEtoposide·Cisplatin·Carboplatin
Sun Yat-sen University
Phase 3
852
Guangzhou, Hangzhou
2025-06-03
Recruiting
Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer
NCT06903858Colorectal Cancer, Microsatellite Instability High, Mismatch Repair Deficiency
DrugsCelecoxib·Toripalimab
Sun Yat-sen University
Phase 2
105
Guangzhou
2025-06-01
Not yet open
Sun Yat-sen University
Phase 3
296
Guangzhou
2025-06-01
Recruiting
Sun Yat-sen University
Phase 1/2
64
Guangzhou
2025-06-01
Active, closed
Sun Yat-sen University
Phase 3
126
Guangzhou
2025-06-01
Recruiting
Sun Yat-sen University
Phase 2
20
Guangzhou
2025-06-01
Recruiting
Sun Yat-sen University
Not applicable
1,598
Guangzhou
2025-06-01
Not yet open
Sun Yat-sen University
Phase 2/3
590
Guangzhou
2025-06-01
Active, closed
Pelvic Floor Peritoneal Closure to Prevent Postoperative Ileus in Mid-Low Rectal Cancer Surgery
NCT07432542Rectal Cancer Surgery, Middle and Low Rectal Cancer, Intestinal Obstruction, Ileus
Sun Yat-sen University
Not applicable
516
Guangzhou
2025-06-01
Recruiting
Sun Yat-sen University
Phase 2
70
Guangzhou
2025-05-16
Recruiting
Safety and Efficacy of Pucotenlimab in pLECC
NCT06969534Lymphoepithelioma-like Carcinoma, Lymphoepithelioma, Carcinoma
DrugPucotenlimab
Sun Yat-sen University
Phase 2
33
Guangzhou
2025-05-15
Recruiting
Sun Yat-sen University
Phase 3
136
Guangzhou
2025-05-15
Recruiting
Sun Yat-sen University
Phase 2
83
Guangzhou
2025-05-10
Recruiting
Risk Assessment for HBV-Related Liver Cancer
NCT07160946HBV-related Liver Cirrhosis
Sun Yat-sen University
Observational
6,000
Guangzhou
2025-05-10
Not yet open
Chemoimmunotherapy With or Without SBRT Before Surgery for Locally Advanced Oral and Oropharyngeal Cancer
NCT06861712Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (SCC), Stereotactic Body Radiation Therapy (SBRT)
Sun Yat-sen University
Phase 2
50
Guangzhou
2025-05-06
Recruiting
An AI Educational Agent for Medical Machine Learning Courses
NCT07449182Medical Education, Artificial Intelligence in Medicine
Sun Yat-sen University
Not applicable
56
Guangzhou
2025-05-01
Not yet open
Sun Yat-sen University
Phase 3
664
Guangzhou
2025-05-01
Not yet open
Sun Yat-sen University
Phase 2
22
Guangzhou
2025-05-01
Not yet open
Sun Yat-sen University
Phase 2
133
Guangzhou
2025-05-01
Not yet open
Sun Yat-sen University
Phase 1/2
30
Guangzhou
2025-04-30
Recruiting
Sun Yat-sen University
Phase 2
88
Guangzhou
2025-04-30
Recruiting
Sun Yat-sen University
Phase 2
32
Guangzhou
2025-04-20
Not yet open
Sun Yat-sen University
Phase 2
72
Guangzhou
2025-04-17
Recruiting
Sun Yat-sen University
Phase 2
29
Guangzhou
2025-04-15
Recruiting
Sun Yat-sen University
Phase 2
50
Guangzhou
2025-04-14
Recruiting
Sun Yat-sen University
Not applicable
860
Guangzhou
2025-04-06
Recruiting
Sun Yat-sen University
Phase 2
134
Guangzhou
2025-04-05
Not yet open
Liver Cancer Prognosis Investigation Study
NCT06623734Liver Neoplasms
Sun Yat-sen University
Observational
5,000
Guangzhou
2025-04-01
Recruiting
Sun Yat-sen University
Phase 1
9
Guangzhou
2025-03-27
Recruiting
Sun Yat-sen University
Phase 2
32
Guangzhou
2025-03-20
Recruiting
Sun Yat-sen University
Phase 2
18
Guangzhou
2025-03-14
Recruiting
Sun Yat-sen University
Phase 2
104
Guangzhou
2025-03-01
Active, closed
Sun Yat-sen University
Phase 2/3
196
Guangzhou
2025-02-21
Recruiting
Sun Yat-sen University
Phase 1
12
Guangzhou
2025-02-21
Active, closed
Sun Yat-sen University
Phase 3
466
Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu
2025-02-17
Recruiting
Sun Yat-sen University
Observational
500
Guangzhou
2025-02-15
Not yet open
Sun Yat-sen University
Phase 2
50
Guangzhou
2025-02-01
Recruiting
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
NCT06855823Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
Sun Yat-sen University
Phase 1/2
33
Guangzhou
2025-01-14
Recruiting
Sun Yat-sen University
Phase 1/2
112
Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai, Guilin, Ganzhou, Nanchang
2025-01-10
Recruiting
Sun Yat-sen University
Phase 2
47
Guangzhou
2025-01-03
Recruiting
Sun Yat-sen University
Phase 2
76
Lanzhou, Guangzhou, Zhengzhou
2025-01-03
Recruiting
Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
NCT06900647Metastatic Breast Cancer, Recurrent Breast Cancer
DrugsCDDP·Bortezomib·Cisplatin
Sun Yat-sen University
Phase 1
20
Guangzhou
2025-01-01
Recruiting
Probiotics in Advanced Urothelial Carcinoma
NCT06904573Advanced Urothelial Carcinoma, Probiotics, Immunotherapy
DrugsEnfortumab Vedotin·Disitamab Vedotin·Toripalimab·Nab-paclitaxel
Sun Yat-sen University
Phase 2
222
Guangzhou, Wuhan
2025-01-01
Not yet open
Sun Yat-sen University
Phase 2/3
398
Guangzhou
2025-01-01
Not yet open
High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ)
NCT06646211Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL)
Sun Yat-sen University
Phase 2
30
Guangzhou
2025-01-01
Recruiting
Sun Yat-sen University
Phase 2
57
Guangzhou
2024-12-31
Recruiting
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
NCT06446154Hepatocellular Carcinoma, Immune Checkpoint Inhibitors, Anti-angiogenic Therapy, Second-line Treatment
DrugFruquintinib
Sun Yat-sen University
Phase 2
36
Guangzhou
2024-12-27
Recruiting
The Optimal Radioimmunotherapy Combinations for Advanced TNBC
NCT06735131Triple-Negative Breast Cancer (TNBC)
DrugToripalimab
Sun Yat-sen University
Phase 2
60
Guangzhou
2024-12-20
Recruiting
Sun Yat-sen University
Phase 2
52
Guangzhou
2024-12-10
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou
2024-12-01
Recruiting
Sun Yat-sen University
Phase 2
97
Guangzhou
2024-12-01
Recruiting
Neoadjuvant Immunotherapy Plus Chemotherapy Followed by Concurrent Chemoradiotherapy and Consolidative Immunotherapy for Locally Advanced Non-small Cell Lung Cancer
NCT06734702Neoadjuvant Therapy, Concurrent Chemoradiotherapy, Immunotherapy, Locally Advanced Non-Small Cell Lung Cancer
Sun Yat-sen University
Phase 3
497
Guangzhou
2024-11-30
Recruiting
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
NCT06719700Toripalimab, Surufatinib, Chemoradiotherapy, Limited-stage Small Cell Lung Cancer (LS-SCLC)
Sun Yat-sen University
Phase 2
47
Guangzhou
2024-11-30
Recruiting
Sun Yat-sen University
Phase 3
242
Guangzhou
2024-11-27
Not yet open
Sun Yat-sen University
Phase 2/3
206
Guangzhou
2024-11-25
Recruiting
Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma
NCT07602049Soft Tissue Sarcoma (STS), Osteosarcoma
Sun Yat-sen University
Phase 2
57
Guangzhou
2024-11-20
Recruiting
A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)
NCT06829147Nasopharyngeal Cancinoma (NPC), Lymph Node Metastasis
Sun Yat-sen University
Observational
500
Guangzhou
2024-11-19
Recruiting
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
NCT06742502Primary Mediastinal Diffuse Large B-cell Lymphoma
Sun Yat-sen University
Phase 2
30
Fuzhou, Guangzhou
2024-11-12
Recruiting
Sun Yat-sen University
Observational
2
Guangzhou
2024-11-04
Not yet open
Sun Yat-sen University
Phase 2
55
Guangzhou
2024-11-02
Recruiting
Sun Yat-sen University
Phase 2
120
Guangzhou
2024-11-01
Recruiting
Sun Yat-sen University
Observational
200
Guangzhou
2024-11-01
Recruiting
Sun Yat-sen University
Phase 1
30
Guangzhou
2024-11-01
Recruiting
Sun Yat-sen University
Phase 2
39
Guangzhou, Lanzhou, Dongguan, Shantou, Shenzhen, Zhaoqing, Zhuhai
2024-11-01
Recruiting
Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer
NCT06520683Colorectal Cancer, Microsatellite Instability High
DrugTislelizumab
Sun Yat-sen University
Phase 3
180
Guangzhou
2024-11-01
Recruiting
Sun Yat-sen University
Not applicable
40
Guangzhou, Dongguan
2024-11-01
Active, closed
Sun Yat-sen University
Phase 2
42
Guangzhou
2024-10-30
Recruiting
Sun Yat-sen University
Phase 2
12
Guangzhou
2024-10-23
Recruiting
Sun Yat-sen University
Phase 2
73
Guangzhou
2024-10-23
Recruiting
Sun Yat-sen University
Phase 2
84
Guangzhou
2024-10-22
By invitation
Sun Yat-sen University
Not applicable
252
Guangzhou
2024-10-15
Active, closed
Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma
NCT06630780Head and Neck Squamous Cell Carcinoma (HNSCC)
Sun Yat-sen University
Not applicable
50
Guangzhou
2024-09-26
Recruiting
Sun Yat-sen University
Phase 3
422
Guangzhou, Guilin, Changsha, Nanjing
2024-09-20
By invitation
Hematoporphyrin Photodynamic Therapy for Esophageal Cancer
NCT06437288Esophageal Cancer, Photodynamic Therapy
Sun Yat-sen University
Phase 4
198
Guangzhou
2024-09-18
Recruiting
Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)
NCT06726421Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic
Sun Yat-sen University
Phase 3
252
Fuzhou, Guangzhou, Wuhan, Changchun, Chengdu, Wenzhou, Beijing, Shanghai
2024-09-18
Recruiting
Sun Yat-sen University
Phase 2
35
Guangzhou
2024-09-11
Recruiting
Sun Yat-sen University
Phase 1
16
Guangzhou
2024-09-03
Recruiting
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
NCT06467799Hepatocellular Carcinoma, Beyond Milan Criteria
Sun Yat-sen University
Phase 2
39
Guangzhou
2024-09-01
Recruiting
Sun Yat-sen University
Not applicable
1,200
Guangzhou
2024-08-10
Recruiting
Sun Yat-sen University
Phase 1
24
Guangzhou
2024-08-02
Recruiting
Sun Yat-sen University
Phase 3
490
Guangzhou
2024-08-01
Recruiting
Sun Yat-sen University
Phase 2
42
Guangzhou, Shanghai
2024-08-01
Recruiting
Sun Yat-sen University
Observational
30
Guangzhou
2024-07-24
Active, closed
Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma
NCT06524466Resectable Hepatocellular Carcinoma, Macrovascular Invasion, CNLC IIIA Stage
Sun Yat-sen University
Phase 2
35
Guangzhou
2024-07-23
Recruiting
Adebrelimab and Chemoradiotherapy in High-risk LANPC
NCT06349889Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
DrugAdebrelimab
Sun Yat-sen University
Phase 2
50
Xiamen, Guangzhou, Chengdu
2024-07-23
Recruiting
Sun Yat-sen University
Phase 2
34
Guangzhou
2024-07-18
Recruiting
Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations
NCT06517953Non-small Cell Lung Cancer Metastatic, EGFR G719X, EGFR L861Q, EGFR S768I
DrugsIcotinib·Befotertinib
Sun Yat-sen University
Phase 2
23
Guangzhou
2024-07-17
Recruiting
Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC
NCT06197776Multi-omics Technique, Nasopharyngeal Carcinoma, Recurrent and Metastatic Nasopharyngeal Carcinoma, Efficacy of Chemoradiotherapy and Immunotherapy
Sun Yat-sen University
Observational
50
Guangzhou
2024-07-15
Recruiting
Sun Yat-sen University
Phase 2
148
Guangzhou
2024-07-15
Recruiting
Sun Yat-sen University
Phase 2
216
Foshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen, Zhangjiang
2024-06-18
Recruiting
Sun Yat-sen University
Phase 1/2
82
Guangzhou
2024-06-06
Recruiting
Sun Yat-sen University
Observational
908
Fuzhou, Guangzhou, Zhongshan, Nanning, Wuzhou
2024-05-29
Recruiting
Sun Yat-sen University
Phase 2/3
84
Guangzhou
2024-05-24
Recruiting
Sun Yat-sen University
Phase 2
38
Guangzhou
2024-05-23
Recruiting
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases
NCT06542159Adaptive Radiotherapy, Stereotactic Body Radiotherapy, Non-small Cell Lung Cancer, Lung Oligometastases
Sun Yat-sen University
Phase 2
130
Guangzhou
2024-05-22
Recruiting
Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma
NCT06516133Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
494
Guangzhou
2024-05-17
Recruiting
Prebiotics and the Management of Hyperuricemia
NCT06420401Subjects With Hyperuricemia
Sun Yat-sen University
Not applicable
160
Guangzhou
2024-05-15
By invitation
Sun Yat-sen University
Not applicable
1,072
Guangzhou
2024-05-06
Not yet open
Sun Yat-sen University
Early Phase 1
12
Guangzhou
2024-05-01
Recruiting
A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
NCT06781151Ovarian Cancer Recurrent, Endometrial Cancer Recurrent, Cervical Cancer Recurrent
Sun Yat-sen University
Observational
200
Guangzhou, Shenzhen
2024-04-24
Recruiting
Individualized Elective Neck Irradiation in NPC Patients
NCT06241612Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3
470
Guangzhou
2024-04-16
Recruiting
Sun Yat-sen University
Phase 2
140
Guangzhou
2024-04-05
Recruiting
Factors Associated With Posttransplant Cardiac Outcomes
NCT06290154Cardiovascular Diseases, Liver Transplantation
Sun Yat-sen University
Observational
200
Guangzhou
2024-04-01
Recruiting
Sun Yat-sen University
Phase 2
162
Guangzhou, Dongguan, Foshan, Shenzhen, Wuhan
2024-03-19
Recruiting
Sun Yat-sen University
Not applicable
112
Guangzhou
2024-03-04
Active, closed
Sun Yat-sen University
Phase 2
46
Guangzhou
2024-03-02
Recruiting
Sun Yat-sen University
Phase 3
593
Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou, Shantou, Zhanjiang, Nanning
2024-03-01
Recruiting
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
NCT06582940MRI-guided Adaptive Radiotherapy, Non-small Cell Lung Cancer, Brain Metastasis
Sun Yat-sen University
Phase 2
168
Guangzhou
2024-03-01
Not yet open
Myeloprotection With Trilaciclib in Pan-cancer Population
NCT06297811Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer, Cervical Cancer
DrugsTrilaciclib·Paclitaxel·Carboplatin
Sun Yat-sen University
Phase 2
132
Guangzhou
2024-03-01
Recruiting
Sun Yat-sen University
Phase 2
140
Guangzhou
2024-03-01
Not yet open
Sun Yat-sen University
Not applicable
176
Guangzhou, Jieyang, Shantou, Zhongshan
2024-03-01
Recruiting
Sun Yat-sen University
Phase 2/3
300
Guangzhou
2024-02-01
Recruiting
Sun Yat-sen University
Phase 2/3
156
Guangzhou
2024-02-01
Recruiting
Sun Yat-sen University
Phase 2
90
Guangzhou
2024-02-01
Not yet open
Sun Yat-sen University
Phase 2
40
Guangzhou
2024-02-01
Recruiting
Sun Yat-sen University
Phase 2
47
Beijing, Guangzhou
2024-01-27
Recruiting
Sun Yat-sen University
Phase 3
117
Guangzhou
2024-01-15
Recruiting
Sun Yat-sen University
Phase 3
302
Guangzhou
2024-01-15
Recruiting
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
NCT05941741Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
DrugCadonilimab
Sun Yat-sen University
Phase 3
380
Guangzhou, Nanning, Nanchang
2024-01-10
Recruiting
Sun Yat-sen University
Phase 2
65
Guangzhou
2024-01-01
Recruiting
The Cold Ischemia Robot-assisted Partial Nephrectomy
NCT07326280Renal Cell Carcinoma, Renal Function Abnormal
Sun Yat-sen University
Not applicable
310
Guangzhou
2024-01-01
Active, closed
Sun Yat-sen University
Observational
300
Guangzhou
2024-01-01
Recruiting
Sun Yat-sen University
Phase 2
88
Guangzhou
2023-12-30
Recruiting
Sun Yat-sen University
Phase 3
200
Guangzhou
2023-12-26
Recruiting
Sun Yat-sen University
Phase 2
60
Guangzhou
2023-12-14
Recruiting
Sun Yat-sen University
Phase 2
25
Guangzhou
2023-12-07
Active, closed
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
NCT05975307Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy
DrugsJS001·Toripalimab·Gemcitabine·Cisplatin
Sun Yat-sen University
Phase 2
64
Guangzhou
2023-12-01
Active, closed
Guangzhou Preterm and Term Birth Cohort Study
NCT07756177Preterm Birth, Neurodevelopmental Disorders, Overweight, Obesity
Sun Yat-sen University
Observational
200
Guangzhou
2023-11-21
Recruiting
Sun Yat-sen University
Phase 2
198
Foshan, Guangzhou, Guiyang
2023-11-09
Recruiting
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
NCT06041477Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
Sun Yat-sen University
Phase 3
540
Guangzhou
2023-10-31
Not yet open
First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer
NCT06063070Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer, Primary Peritoneal Cancer
DrugsFluzoparib·Bevacizumab
Sun Yat-sen University
Phase 2
44
Guangzhou
2023-10-18
Recruiting
Sun Yat-sen University
Phase 3
504
Guangzhou
2023-10-09
Recruiting
Sun Yat-sen University
Phase 2
108
Guangzhou
2023-10-01
Recruiting
Evaluation of Phacogoniotomy in Medically-controlled POAG
NCT06201455Glaucoma, Open-Angle, Cataract Complicated, Goniotomy
Sun Yat-sen University
Not applicable
100
Guangzhou
2023-09-28
Active, closed
Sun Yat-sen University
Phase 3
464
Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan, Changsha
2023-09-07
Active, closed
Sun Yat-sen University
Phase 2
59
Guangzhou
2023-09-01
Recruiting
Sun Yat-sen University
Not applicable
392
Guangzhou
2023-09-01
Recruiting
Sun Yat-sen University
Phase 2
43
Guangzhou
2023-09-01
Active, closed
Sun Yat-sen University
Phase 1
18
Guangzhou
2023-08-31
Recruiting
Sun Yat-sen University
Phase 2
54
Guangzhou
2023-08-24
Active, closed
Sun Yat-sen University
Not applicable
620
Beijing, Fuzhou, Lanzhou, Dongguan, Foshan, Guangzhou, Wuhan, Nanjing
2023-08-16
Active, closed
Sun Yat-sen University
Phase 1/2
44
Guangzhou
2023-08-15
Active, closed
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
NCT05780372Nasopharyngeal Carcinoma, Radiotherapy; Complications
Sun Yat-sen University
Phase 3
474
Chongqing, Dongguan, Guangzhou, Liuzhou, Nanning, Nanchang, Hangzhou
2023-08-08
Active, closed
Sun Yat-sen University
Observational
2,600
Guangzhou
2023-08-02
Active, closed
Sun Yat-sen University
Phase 3
490
Bengbu, Hefei, Beijing, Fuzhou, Dongguan, Guangzhou, Zhongshan, Nanning
2023-08-01
Recruiting
Sun Yat-sen University
Not applicable
50
Guangzhou
2023-08-01
Recruiting
Sun Yat-sen University
Not applicable
349
Guangzhou
2023-07-26
Recruiting
Sun Yat-sen University
Phase 2
143
Guangzhou
2023-07-10
Recruiting
Sun Yat-sen University
Phase 2/3
346
Guangzhou
2023-07-01
Recruiting
PaCIFiC-CUP Classifies Cancer of Unknown Primary
NCT06140992Unknown Primary Tumors, DNA Methylation
Sun Yat-sen University
Observational
120
Guangzhou
2023-07-01
Active, closed
Effect of IOP Lowering on Progressive HM
NCT05850936High Myopia, Intraocular Pressure
Sun Yat-sen University
Not applicable
152
Guangzhou
2023-06-01
Recruiting
Effects of Digital Therapeutic in Whole Process Management of Lung Cancer
NCT06230445Application of Digital Therapeutic in Lung Cancer Whole Process Management
Sun Yat-sen University
Phase 3
900
Guangzhou
2023-06-01
Recruiting
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma
NCT07644897Melanoma, Immune-related Adverse Event, Immune Checkpoint Inhibitor
Sun Yat-sen University
Phase 2
55
Guangzhou, Shenzhen
2023-05-30
Recruiting
Sun Yat-sen University
Phase 3
424
Guangzhou
2023-05-20
Recruiting
Sun Yat-sen University
Phase 2
53
Guangzhou
2023-05-17
Active, closed
Sun Yat-sen University
Phase 2
30
Guangzhou
2023-05-10
Active, closed
Sun Yat-sen University
Phase 2
32
Guangzhou
2023-05-08
Recruiting
Sun Yat-sen University
Phase 3
244
Guangzhou
2023-05-01
Recruiting
Sun Yat-sen University
Phase 3
540
Guangzhou, Guiyang, Harbin, Zhengzhou, Wuhan, Nanchang, Dalian, Shanghai
2023-04-30
Not yet open
Sun Yat-sen University
Phase 3
132
Guangzhou
2023-04-01
Recruiting
Sun Yat-sen University
Phase 2
55
Guangzhou
2023-03-09
Recruiting
Evaluation of COVID-19 Immune Barrier and Reinfection Risk
NCT05774093COVID-19 Infection, Immunization; Infection
Sun Yat-sen University
Observational
300
Guangzhou
2023-03-06
Recruiting
Sun Yat-sen University
Phase 3
176
Hefei, Foshan, Guangzhou, Nanning, Harbin, Zhengzhou, Nanchang, Shanghai
2023-03-01
Recruiting
Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
NCT06788353Transarterial Chemoembolization, Systemic Therapy, Unresectable Hepatocellular Carcinoma
Sun Yat-sen University
Observational
500
Guangzhou
2023-03-01
Not yet open
Sun Yat-sen University
Phase 3
136
Guangzhou
2023-03
Recruiting
Sun Yat-sen University
Observational
30
Guangzhou
2023-02-15
Active, closed
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
NCT05426005Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H)
DrugCadonilimab
Sun Yat-sen University
Phase 1/2
28
Guangzhou
2023-02-07
Recruiting
Sun Yat-sen University
Phase 2
36
Guangzhou
2023-02-01
Active, closed
Sun Yat-sen University
Phase 2
32
Guangzhou
2022-12-12
Not yet open
Sun Yat-sen University
Not applicable
236
Guangzhou
2022-11-30
Active, closed
Sun Yat-sen University
Phase 2
41
Guangzhou
2022-11-25
Active, closed
Compression Therapy as a Prophylactic Method Against CIPN: a Prospective Self-controlled Trial
NCT05531916Nasopharyngeal Carcinoma, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Sun Yat-sen University
Not applicable
182
Guangzhou
2022-11-21
Recruiting
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
NCT05357846Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer
DrugsTaxol·Sintilimab·Paclitaxel·Cisplatin
Sun Yat-sen University
Phase 3
422
Guangzhou
2022-11-01
Not yet open
Effect of Prebiotics on Blood Pressure Management
NCT05364736Hypertension, Gastrointestinal Microbiome
Sun Yat-sen University
Not applicable
100
Guangzhou
2022-10-17
Recruiting
Sun Yat-sen University
Observational
800
Fuzhou, Dongguan, Foshan, Guangzhou, Shantou, Shaoguan, Shenzhen, Zhongshan
2022-10-10
Active, closed
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
NCT05520619Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma
DrugsPaclitaxel, Cisplatin·Taxol·Tislelizumab
Sun Yat-sen University
Phase 2
114
Guangzhou
2022-09-15
Active, closed
Sun Yat-sen University
Phase 2
105
Guangzhou
2022-08-17
Active, closed
Sun Yat-sen University
Phase 2
47
Guangzhou
2022-08-01
Recruiting
Sun Yat-sen University
Phase 2
194
Guangzhou
2022-07-29
Active, closed
Sun Yat-sen University
Phase 2
84
Guangzhou
2022-07-15
Recruiting
Sun Yat-sen University
Observational
11,625
Guangzhou
2022-07-10
Recruiting
Sun Yat-sen University
Phase 3
766
Chongqing, Guangzhou, Hengyang, Shenyang, Xi'an, Nanchong
2022-07-05
Active, closed
Sun Yat-sen University
Phase 1/2
46
Beijing, Dalian, Guangzhou, Nanchang
2022-06-23
Recruiting
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05430399Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
DrugsUtidelone·Docetaxel
Sun Yat-sen University
Phase 3
349
Guangzhou, Hunan
2022-06-21
Recruiting
Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
NCT05397769Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemotherapy, PD-L1
DrugEnvafolimab
Sun Yat-sen University
Phase 2
36
Guangzhou
2022-06-08
Recruiting
Sun Yat-sen University
Observational
500
Guangzhou
2022-06-01
Recruiting
Sun Yat-sen University
Not applicable
264
Guangzhou
2022-06-01
Not yet open
Umbrella Biomarker-Guided Therapy in NPC
NCT04605562Nasopharyngeal Carcinoma
DrugsGalunisertib·Palbociclib
Sun Yat-sen University
Phase 2
206
Guangzhou
2022-06
Active, closed
Sun Yat-sen University
Phase 2
150
Guangzhou
2022-05-17
Active, closed
Sun Yat-sen University
Phase 3
452
Guangzhou
2022-05-11
Recruiting
Sun Yat-sen University
Phase 2
280
Changchun, Chengdu, Dongguan, Dongyang, Foshan, Guangzhou, Hangzhou, Jiangmen
2022-05-06
Recruiting
Sun Yat-sen University
Observational
200
Guangzhou
2022-04-25
Active, closed
Sun Yat-sen University
Phase 2
46
Guangzhou
2022-04-24
Recruiting
Sun Yat-sen University
Phase 3
556
Guangzhou
2022-04-17
Recruiting
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2022-04-01
Recruiting
Sun Yat-sen University
Phase 3
280
Guangzhou
2022-03-14
Not yet open
Sun Yat-sen University
Phase 3
512
Guangzhou
2022-03-01
Active, closed
Sun Yat-sen University
Phase 2
44
Guangzhou
2022-02-28
Active, closed
Sun Yat-sen University
Phase 3
214
Guangzhou
2022-01-17
Active, closed
Sun Yat-sen University
Observational
220
Guangzhou
2022-01-15
Active, closed
Sun Yat-sen University
Phase 2
51
Guangzhou
2022-01-11
Recruiting
Sun Yat-sen University
Observational
200
Guangzhou
2022-01-01
By invitation
Sun Yat-sen University
Observational
58
Guangzhou
2022-01-01
Recruiting
Sun Yat-sen University
Phase 1
39
Guangzhou
2022-01-01
Recruiting
Sun Yat-sen University
Phase 3
323
Guangzhou
2022-01-01
Recruiting
Multi-model Image of Doxycycline in TAO
NCT05112211Thyroid Associated Ophthalmopathy
DrugDoxycycline Hyclate
Sun Yat-sen University
Not applicable
20
Guangzhou
2022-01-01
By invitation
Sun Yat-sen University
Observational
855
Guangzhou
2021-12-30
Recruiting
Sun Yat-sen University
Phase 2
37
Guangzhou
2021-12-29
Active, closed
Sun Yat-sen University
Phase 2
47
Guangzhou
2021-12-10
Recruiting
Sun Yat-sen University
Observational
60
Guangzhou
2021-12-01
Recruiting
Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
NCT05194878Colon Cancer Stage II, Colon Cancer Stage III
Sun Yat-sen University
Phase 3
840
Guangzhou
2021-12-01
Recruiting
Minocycline for Chronic Autoimmune Uveitis
NCT05474729Minocycline, Uveitis, Retinal Degeneration
DrugMinocycline
Sun Yat-sen University
Phase 1/2
10
Guangzhou
2021-12-01
Recruiting
Sun Yat-sen University
Observational
1,000
Guangzhou
2021-10-01
Recruiting
Sun Yat-sen University
Phase 3
266
Guangzhou
2021-08-16
Recruiting
Sun Yat-sen University
Phase 2
30
Guangzhou
2021-08-13
Recruiting
Sun Yat-sen University
Phase 2
32
Guangzhou
2021-08-01
Active, closed
Sun Yat-sen University
Phase 3
532
Beijing, Chongqing, Foshan, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2021-08-01
Active, closed
Sun Yat-sen University
Phase 2
150
Bengbu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai
2021-07-21
Not yet open
Sun Yat-sen University
Phase 2/3
622
Guangzhou
2021-07-01
Recruiting
Sun Yat-sen University
Phase 2
100
Guangzhou
2021-06-23
Active, closed
Sun Yat-sen University
Phase 2
266
Guangzhou
2021-06-16
Active, closed
Sun Yat-sen University
Phase 1/2
36
Guangzhou
2021-06-16
Active, closed
Sun Yat-sen University
Observational
231
Guangzhou
2021-06-05
Recruiting
Sun Yat-sen University
Phase 3
524
Guangzhou
2021-06-01
Recruiting
Sun Yat-sen University
Phase 3
188
Guangzhou
2021-06-01
Active, closed
Sun Yat-sen University
Not applicable
124
Guangzhou, Guangdong
2021-05-31
Recruiting
Sun Yat-sen University
Phase 2
69
Guangzhou
2021-05-21
Active, closed
Sun Yat-sen University
Phase 1
40
Guangzhou
2021-04-19
Recruiting
Sun Yat-sen University
Observational
300
Guangzhou
2021-04-01
Recruiting
Topotecan and Melphalan for Retinoblastoma
NCT04799002Retinoblastoma, Chemotherapy Effect
DrugsMelphalan·Topotecan
Sun Yat-sen University
Phase 3
50
Guangzhou
2021-03-11
Recruiting
Sun Yat-sen University
Phase 3
218
Guangzhou, Zhongshan, Nanchang
2021-03-03
Recruiting
Sun Yat-sen University
Observational
2,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2021-03-01
Recruiting
Sun Yat-sen University
Not applicable
320
Guangzhou
2021-02-20
Recruiting
Lymphadenectomy in Early Ovarian Cancer
NCT04710797Ovarian Cancer, Lymphadenectomy
Sun Yat-sen University
Not applicable
656
Guangzhou
2021-01-31
Active, closed
Sun Yat-sen University
Phase 2
30
Guangzhou
2021-01-01
Recruiting
Postoperative Hypoxemia Increases the Risk of Anastomotic Leak After Radical Esophagectomy
NCT07309991Esophageal Carcinoma, Esophageal Adenocarcinoma, Esophagectomy, PaO2
Sun Yat-sen University
Observational
2,500
Guangzhou, Shantou, Shijiazhuang, Shanghai, Chengdu, Nanchong
2021-01-01
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou
2020-12-01
Active, closed
Sun Yat-sen University
Phase 2
42
Guangzhou
2020-12-01
Recruiting
Sun Yat-sen University
Phase 2
43
Guangzhou
2020-11-17
Recruiting
Sun Yat-sen University
Phase 3
500
Guangzhou
2020-11-01
Recruiting
Toripalimab Combined With CAV/IE Regimen
NCT04589741Soft Tissue Sarcoma
DrugToripalimab
Sun Yat-sen University
Phase 2
134
Guangzhou
2020-10-23
Recruiting
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
NCT04453826Nasopharyngeal Cancer, Chemotherapy, Radiotherapy, PD-1 Therapy
DrugCamrelizumab
Sun Yat-sen University
Phase 3
388
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-09-01
Active, closed
Sun Yat-sen University
Not applicable
1,124
Chongqing, Lanzhou, Guangzhou, Shenzhen, Guilin, Zhengzhou, Wuhan, Nanjing
2020-08-25
Recruiting
Sun Yat-sen University
Phase 3
508
Guangzhou, Shaoguan, Zhongshan, Wuzhou
2020-08-18
Active, closed
Sun Yat-sen University
Phase 3
381
Guangzhou
2020-08-17
Recruiting
Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
NCT04453813Nasopharyngeal Carcinoma, Chemotherapy, Radiotherapy, PD-1 Treatment
DrugToripalimab
Sun Yat-sen University
Phase 3
226
Guangzhou, Shaoguan, Zhongshan, Zhuhai, Wuzhou
2020-07-03
Recruiting
Sun Yat-sen University
Not applicable
500
Guangzhou, Zhuhai, Nanchang
2020-06-30
Recruiting
Sun Yat-sen University
Phase 3
207
Guangzhou
2020-05-03
Recruiting
Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC
NCT04544969Circulating Tumor Cell, Nasopharyngeal Carcinoma, Distant Metastases.Clinical, Effects of Chemotherapy
Sun Yat-sen University
Observational
50
Guangzhou
2020-04-01
Active, closed
Sun Yat-sen University
Phase 2
68
Guangzhou
2020-03-12
Recruiting
Sun Yat-sen University
Phase 3
212
Guangzhou, Beijing, Chengdu, Fuzhou, Guiyang, Hangzhou, Nanchang, Nanning
2020-03-01
Active, closed
Sun Yat-sen University
Phase 2
246
Guangzhou
2020-01-31
Recruiting
Sun Yat-sen University
Phase 3
346
Guangzhou
2020-01-01
Recruiting
Sun Yat-sen University
Observational
700
Guangzhou
2020-01-01
Active, closed
Sun Yat-sen University
Phase 2
34
Guangzhou
2019-10-09
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou
2019-09-01
Active, closed
Sun Yat-sen University
Observational
813
Guangzhou
2019-06-06
Recruiting
Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
NCT03926338Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H), Neoadjuvant Therapy
DrugsNeoadjuvant toripalimab·Toripalimab
Sun Yat-sen University
Phase 2
270
Guangzhou
2019-05-10
Active, closed
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03840421Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
DrugsGemcitabine and cisplatin·Cisplatin
Sun Yat-sen University
Phase 3
468
Guangzhou
2019-04-03
Active, closed
Sun Yat-sen University
Phase 2
40
Guangzhou
2019-03-25
Recruiting
Sun Yat-sen University
Phase 2
36
Guangzhou
2019-03-01
Active, closed
Sun Yat-sen University
Phase 3
360
Guangzhou, Jieyang, Shantou, Zhongshan, Chengdu, Shanghai
2019-02-21
Recruiting
Sun Yat-sen University
Phase 2
35
Guangzhou, Guiyang, Wuhan, Dalian
2019-01-15
Active, closed
TNT to Increase the Clinical Complete Response Rate for Distal LARC
NCT03840239Rectal Cancer, Rectal Cancer Stage II, Rectal Cancer Stage III, Chemoradiation
DrugCapecitabine, Oxaliplatin
Sun Yat-sen University
Phase 2
98
Guangzhou
2018-12-25
Recruiting
Sun Yat-sen University
Phase 3
776
Guangzhou
2018-11-16
Recruiting
Sun Yat-sen University
Phase 3
794
Guangzhou
2018-07-25
Recruiting
Nanshan Elderly Cohort Study
NCT03569735Hypertension, Type 2 Diabetes Mellitus, Cardiovascular Diseases, Stroke
Sun Yat-sen University
Observational
20,000
Shenzhen, Guangzhou
2018-05-26
Active, closed
Sun Yat-sen University
Phase 2
146
Guangzhou
2018-04-15
Active, closed
TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma
NCT03306121Nasopharyngeal Carcinoma
DrugCCRT
Sun Yat-sen University
Phase 3
322
Guangzhou
2017-11-13
Recruiting
Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
NCT03353467Nasopharyngeal Carcinoma, Endoscopic Surgery, Primary Napharyngeal Carcinama, Stage I Nasopharyngeal Cancer
Sun Yat-sen University
Not applicable
228
Guangzhou, Zhongshan, Nanning
2017-10-01
Active, closed
Sun Yat-sen University
Phase 2
164
Guangzhou
2017-02-04
Recruiting
IgA Nephropathy Biomarkers Evaluation Study (INTEREST)
NCT02954419IgA Nephropathy, Glomerular Diseases
Sun Yat-sen University
Observational
2,000
Guangzhou
2016-11
Recruiting
MItral Regurgitation Risk Assessment and CLinical modElling
NCT06876883Mitral Insufficiency, Mitral Regurgitation (MR)
Sun Yat-sen University
Observational
2,000
Guangzhou
2016-06-15
Recruiting
Tricuspid RegurgitAtion rIsk modeL Study (TRAIL Study)
NCT06926959Tricuspid Regurgitation
Sun Yat-sen University
Observational
3,000
Guangzhou, Jieyang, Shantou, Shenzhen, Zhanjiang, Zhongshan
2016-06-15
Recruiting
Esthetic, Clinical and Radiographic Outcomes of Immediate and Delayed Implant Placement
NCT02814149Jaw, Edentulous, Partially, Acquired Absence of Single Tooth
Sun Yat-sen University
Not applicable
40
Guangzhou
2016-05
Active, closed
Sun Yat-sen University
Not applicable
15
Guangzhou
2016-05
Recruiting
Sun Yat-sen University
Observational
5,000
Guangzhou
2016-04
Recruiting
Sun Yat-sen University
Phase 3
230
Guangzhou
2016-01-01
Active, closed
Sun Yat-sen University
Not applicable
1,080
Guangzhou
2015-12-31
Active, closed
Sun Yat-sen University
Phase 3
236
Guangzhou
2015-06
Active, closed
Sun Yat-sen University
Phase 3
738
Guangzhou
2015-01-01
Recruiting
REal-world Data of CARdiometabolic ProtEcTion
NCT07038083Cardiometabolic Diseases
Sun Yat-sen University
Observational
40,000
Guangzhou
2014-01-01
Recruiting
Peritoneal Dialysis Registration System (PERSIST)
NCT02989298ESRD, Disorders Associated With Peritoneal Dialysis
Sun Yat-sen University
Observational
10,000
Guangzhou
2013-12
Recruiting
Wise Practice of Chinese Hemodialysis (WISHES)
NCT03001921Haemolyses and Related Conditions
Sun Yat-sen University
Observational
30,000
Guangzhou
2013-12
Recruiting
Sun Yat-sen University
Observational
5,000
Guangzhou
2013-11
Recruiting
Sun Yat-sen University
Observational
30,000
Guangzhou
2013-01-01
Recruiting
Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery
NCT01653223Congenital Heart Disease, Heart Valve Disease
DrugSimvastatin
Sun Yat-sen University
Not applicable
369
Guangzhou
2013-01
Recruiting
Sun Yat-sen University
Observational
10,000
Guangzhou
2012-11
Recruiting
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
NCT01994057Non-small Cell Lung Cancer (NSCLC), EGFR-TKI Resistant Mutation, EGFR-TKI Sensitizing Mutation, Germline Mutations
Sun Yat-sen University
Observational
1,000
Guangzhou
2012-09
Recruiting
A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC
NCT03303495Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms, Gastrointestinal Neoplasms
Drugs5 FU bolus·Avastin·Fluorouracil·Leucovorin
Sun Yat-sen University
Phase 3
280
Guangzhou
2011-11-14
Recruiting
The New Serial Treatment of Temporomandibular Disorders
NCT00932594Temporomandibular Disorder
Sun Yat-sen University
Not applicable
4
Guangzhou
2006-01
Recruiting
The Chinese Pulmonary Lymphoepithelioma-like Carcinoma Collaboration Study
NCT06801977Primary Pulmonary Lymphoepithelioma-like Carcinoma
Sun Yat-sen University
Observational
10,000
Foshan, Guangzhou
2002-01-01
Rows per page Showing 1–444 of 444
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 444 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

268 of the 444 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 96 have not yet opened recruitment, 72 are active but closed to new participants, and 8 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 444 studies
PhaseStudiesRecruitingShare
Phase 220311445.7%
Phase 3896220%
Observational614413.7%
Not applicable512611.5%
Phase 1/21683.6%
Phase 11192.5%
Phase 2/31052.3%
Early Phase 1200.5%
Phase 4100.2%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Sun Yat-sen University444268
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.